FibroScan®
Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a common disorder affecting up to one-third of adults in the United States. Obesity and associated Type 2 diabetes mellitus (T2DM) are known to be the most common cause of fatty infiltration of the liver, with NAFLD-NASH being strongly associated to the features of metabolic syndrome.
FibroScan® Guided Fatty Liver Chronic Care Management Services Provide Effective Early-Stage Disease Management Solutions
Dr. Hogan’s team at Gastrointestinal Associates (GIA), the largest gastroenterology practice in Mississippi and one of the largest in the Southeastern United States, uses FibroScan® to identify early stage fatty liver disease in at-risk patients with T2DM, metabolic syndrome and central obesity. Qualified patients receive chronic care management (CCM) services which are orchestrated to achieve 5-7% weight lose via a digitally-based lifestyle modification program. Digital CCM services are provided by MetaPhy Health, a physician services group focused on assisting gastroenterologists with their efforts to manage NAFLD-NASH patients, in a manner which relieves the GI practice from the workload while optimizing clinical efficacy.
FibroScan® data, with a focus on CAP score data, is used both to qualify patients for the digital lifestyle modification program and to monitor therapeutic response in a manner which is motivational to the patient as they concurrently lose weight and improve liver steatosis.
Profitable Lifestyle Modification Ancillary Services
A digitally based lifestyle modification ancillary service provides short term profits to the private GI practice while providing an effective clinical solution to detect early stage NAFLD and manage disease progression in a cost-effective manner. These solutions conserve healthcare resources by virtue of early disease detection and financially efficient disease management services which leverage state of the art diagnostics and digital health management services.
